UK 2026 private Iluvien costs a projected £6,500–£8,500 per eye, inclusive of the consultant retinal assessment, OCT imaging, the implant itself and the in-clinic injection procedure. Iluvien is a non-bioerodible intravitreal implant containing fluocinolone acetonide 0.19mg that releases a continuous micro-dose of corticosteroid into the back of the eye for up to 36 months. It is used for chronic or recurrent diabetic macular oedema — swelling at the centre of the retina caused by diabetes — particularly in eyes that have not responded adequately to anti-VEGF injections or laser. Because a single implant lasts around three years, the effective annual cost works out at roughly £2,200–£2,800 per year, often with far fewer clinic visits than repeated injections.
Iluvien prices
Iluvien is administered as a one-off intravitreal implant per eye. The total self-pay cost reflects the high acquisition cost of the sustained-release implant plus the injection procedure and the monitoring that a long-acting steroid requires. Our projected pricing is all-inclusive:
Because diabetic macular oedema is a medical condition rather than a lifestyle one, many patients with private medical insurance have cover for assessment and treatment — see insured patients for how we handle authorisation, and finance for stage-payment options. Compare the alternative retinal treatments on the Ozurdex implant and anti-VEGF injection price pages and the wider prices index.
Living with persistent diabetic macular swelling? A consultant retinal assessment with OCT shows whether a long-acting Iluvien implant is the right next step for your eye.
Book a retinal assessmentWhat is Iluvien and how does it work?
Iluvien is a sustained-release intravitreal implant developed by Alimera Sciences for the treatment of chronic diabetic macular oedema. Diabetic macular oedema (DMO, also written DME) is a build-up of fluid in the macula — the central part of the retina responsible for sharp, detailed vision — driven by diabetic damage to the tiny retinal blood vessels. It is a leading cause of sight loss in working-age adults.
The implant is a minute non-dissolving cylinder, about 3.5mm long, that is injected into the vitreous gel through a fine 25-gauge applicator. Once in place it releases fluocinolone acetonide, a potent corticosteroid, at a very low, steady rate for up to 36 months. The steroid reduces the inflammation and vascular leakage that cause the macula to swell, helping to dry the retina and stabilise — and often improve — vision. The key advantage over short-acting injections is duration: one implant can replace many repeated treatments and the clinic visits that go with them. Iluvien is typically reserved for eyes that have had an insufficient response to other therapies such as anti-VEGF injections or macular laser.
What is included in your Iluvien treatment
- Consultant retinal assessment — a medical retina specialist reviews your diabetic eye disease and prior treatment, see what to expect at your consultation, and confirms whether Iluvien is appropriate.
- OCT macular imaging — high-resolution optical coherence tomography to measure the central macular thickness and document the oedema before and after treatment.
- Lens and pressure check — assessment of the natural lens (steroids can accelerate cataract) and a baseline intraocular pressure, as a small proportion of patients develop a steroid-related pressure rise.
- The Iluvien implant and injection — the implant is delivered as a clean in-clinic intravitreal injection under local anaesthetic drops, taking only a few minutes.
- Post-implant monitoring — scheduled reviews with repeat OCT and pressure checks, because the steroid acts over three years and intraocular pressure must be monitored throughout.
- Integrated diabetic eye care — a clear plan linking your implant to ongoing diabetic retinopathy surveillance and, where needed, anti-VEGF therapy or laser.
What does the evidence say about Iluvien?
Iluvien’s approval for chronic diabetic macular oedema was based on the FAME (Fluocinolone Acetonide in Diabetic Macular Edema) phase 3 programme, two large randomised controlled trials that followed patients for three years. These studies showed that a significantly greater proportion of patients treated with the fluocinolone implant achieved a meaningful improvement in best-corrected visual acuity compared with sham, with the benefit sustained across the 36-month period — the basis on which Iluvien is positioned for chronic DMO insufficiently responsive to available therapies.
The principal trade-offs are well characterised steroid effects. Almost all phakic eyes (those with their natural lens) develop or progress cataract over the implant’s lifespan and many will need cataract surgery, which is why Iluvien is often used in eyes that are already pseudophakic or are planned for lens surgery. A proportion of patients experience a rise in intraocular pressure that requires pressure-lowering drops, and a small number need glaucoma surgery, so lifelong pressure monitoring is essential. These risks are the reason Iluvien is a specialist, carefully selected treatment rather than a first-line option.
Iluvien vs other DMO treatments
Diabetic macular oedema can be treated with anti-VEGF injections, shorter-acting steroid implants, sustained-release steroid implants and macular laser, often in combination. Your retinal consultant will tailor the choice to your oedema pattern, lens status, eye pressure and how you have responded to previous treatment.
| Option | Mechanism | Duration | Key trade-off |
|---|---|---|---|
| Iluvien (fluocinolone 0.19mg) | Non-bioerodible sustained-release corticosteroid implant | Up to 36 months per implant | Cataract progression and possible pressure rise; reserved for chronic DMO |
| Ozurdex (dexamethasone) | Biodegradable corticosteroid implant | Around 3–6 months per implant | Repeat implants needed; similar steroid cataract and pressure effects |
| Anti-VEGF (e.g. faricimab/Vabysmo) | Blocks VEGF-driven vascular leakage | Every 1–4 months, ongoing | Frequent injections and visits; first-line for most DMO |
| Aflibercept 8mg (Eylea HD) | High-dose anti-VEGF with extended intervals | Up to ~4 months between doses | Still an injection programme; ongoing monitoring |
| Macular / focal laser | Seals leaking microaneurysms | One or more sessions | Adjunct for focal oedema; less effective for diffuse central DMO |
Iluvien is generally considered when DMO is chronic or recurrent and has not responded sufficiently to anti-VEGF and laser, especially in pseudophakic eyes. For related retinal injection therapy in vein occlusion, see retinal vein occlusion injections, and for wet AMD see anti-VEGF wet AMD injections.
Are you a candidate for Iluvien?
Good candidates are adults with chronic or recurrent diabetic macular oedema that persists despite prior anti-VEGF therapy or laser, particularly those who are pseudophakic (already had cataract surgery) or are willing to accept that cataract surgery may be needed, who have a normal or well-controlled intraocular pressure, and who would benefit from a long-acting treatment that reduces injection burden. Better suited to other options are patients with treatment-naive DMO (usually treated first with anti-VEGF), those with pre-existing glaucoma or a known strong steroid pressure response, and those who prefer to avoid steroid-related cataract progression. A consultant retinal assessment with OCT determines suitability.
Risks and monitoring
As a long-acting intravitreal corticosteroid, Iluvien carries two main expected effects that require planning and monitoring. Cataract: most phakic eyes develop or progress cataract over the three-year course, and cataract surgery may be required — this is why the implant is frequently used in eyes that are already pseudophakic. Raised intraocular pressure: a proportion of patients develop a steroid-induced pressure rise that needs pressure-lowering drops, and a small minority require glaucoma surgery, so regular pressure checks continue for the life of the implant. As with any intravitreal injection there is a small risk of infection (endophthalmitis), retinal detachment or vitreous floaters; any sudden drop in vision, increasing pain or marked redness after the injection needs urgent review. Your consultant will discuss these risks in full before treatment.
NHS, insurance and funding
Iluvien is available on the NHS for chronic diabetic macular oedema that is insufficiently responsive to available therapies, within defined criteria, and many patients are treated this way. Private treatment offers faster assessment, continuity of consultant care and flexible scheduling. Because diabetic macular oedema is a medical condition, it is frequently covered by UK private medical insurers — see insured patients for how we handle pre-authorisation. Self-pay patients can spread the cost via finance. See the full retinal pathway on the treatments hub and the prices index.
Iluvien frequently asked questions
How much does Iluvien cost privately in the UK in 2026?
How long does an Iluvien implant last?
How is Iluvien different from Ozurdex?
Will Iluvien cause a cataract?
Does Iluvien raise eye pressure?
Is the Iluvien injection painful?
Is Iluvien available on the NHS?
Where can I have private Iluvien treatment in the UK?
Methodology and sources
Pricing is taken from a 2026 UK private ophthalmology and intravitreal therapy tariff review and is presented as a typical projected self-pay range per eye, inclusive of consultant assessment, OCT, the implant and the injection procedure. Clinical statements are drawn from the Iluvien (fluocinolone acetonide 0.19mg) prescribing information, the FAME phase 3 randomised controlled trial programme, NICE technology appraisal guidance on fluocinolone acetonide for chronic diabetic macular oedema, and Royal College of Ophthalmologists guidance on diabetic retinopathy and intravitreal therapy. Page last reviewed 12 June 2026 against the live URL set on eyesurgeryclinic.co.uk.